Predictive Response to Chemotherapy (FOLFOX or FOLFIRI) by ex Vivo Culture 3D Technique in Metastatic Colorectal Cancer (CULTURE3D)
Predictive Response to Chemotherapy (FOLFOX or FOLFIRI) by ex Vivo Culture 3D Technique in Metastatic Colorectal Cancer: a Preliminary Study
調査の概要
詳細な説明
The CULTURE 3D study is a prospective, open labelled, multicenter trial. The aim is to evaluate the feasibility of ex vivo culture 3D (chemogram) on biopsies in order to estimate the predictive value of this technique for treatment response in patients treated by two different chemotherapies (FOLFOX or FOLFIRI) for colorectal cancer.
Patients will have biopsies in a metastasis or in the primitive tumor before treatment. The sample will be used for a 3D ex vivo cells culture. A chemogram will be made based on cells proliferation data (Ki67) and apoptosis (M30).
Results from this chemogram will not interfere with the treatment combination choice.
The treatment response will be evaluated by the RECIST assessment and will be then compared to the chemogram.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Paris、フランス、75005
- Institut Curie
-
Paris、フランス、75475
- Hopital Lariboisiere
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Aged 18 years old or more
- Colorectal cancer with synchronous or metachronous metastases
- Metastasis and/or primitive tumor (in case of synchronous metastases) accessible to biopsy
- Measurable metastatic disease (echography, CT and/or MRI, PET-FDG)
- Indication for treatment with a combination including FOLFOX/FOLFIRI associated to an anti VEGF drug (Avastin)
- No adjuvant chemotherapy for the primitive colorectal cancer and no line of chemotherapy for metastatic disease during the year prior to inclusion.
- Life expectancy > 3 months (ECOG 0-1-2).
- Informed and signed consent by the patient.
Exclusion Criteria:
- Elevation of Carcinoembryonic antigen (CEA) without measurable metastatic disease
- Medical contraindication to chemotherapy or biotherapy as FOLFOX/FOLFIRI or Avastin.
- Treatment with FOLFOX/FOLFIRI and biotherapy anti-EGFR (epidermal growth factor receptor)(Erbitux) planned
- Patient already enrolled in an other clinical trial with another first line of chemotherapy.
- Pregnant women, breastfeeding or of childbearing age not taking contraceptive
- Persons deprived of liberty.
- Subject unable to make follow up schedule
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:biopsy to obtain a chemogram
|
All patients enrolled will have biopsies (on primary tumor or on a metastasis) before treatment in order to obtain a chemogram by ex vivo 3D culture cells
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Number of interpretable chemogram
時間枠:through study completion, an average of 1 year
|
In ex vivo 3D culture from tumor biopsies, number of interpretable chemogram.
|
through study completion, an average of 1 year
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Correlation between chemogram results obtained by 3D culture and RECIST 1.1 response assessement.
時間枠:through study completion, an average of 1 year
|
Number of chemogram showing the same response to treatment than patient RECIST 1.1 measured response.
|
through study completion, an average of 1 year
|
Chemosensitivity evaluated on 3D culture.
時間枠:through study completion, an average of 1 year
|
on untreated and treated fragments : proliferating index (ki67) and apoptosis (M30) will be assessed.
|
through study completion, an average of 1 year
|
time to obtain chemogram
時間枠:through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Pascale Mariani, MD、Institut Curie
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
大腸がんの臨床試験
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Highlight Therapeutics積極的、募集していない平滑筋肉腫 | 悪性末梢神経鞘腫瘍 | 滑膜肉腫 | 未分化多形肉腫 | 骨の未分化高悪性度多形肉腫 | 粘液線維肉腫 | II期の体幹および四肢の軟部肉腫 AJCC v8 | III期の体幹および四肢の軟部肉腫 AJCC v8 | IIIA 期の体幹および四肢の軟部肉腫 AJCC v8 | IIIB 期の体幹および四肢の軟部肉腫 AJCC v8 | 切除可能な軟部肉腫 | 多形性横紋筋肉腫 | 切除可能な脱分化型脂肪肉腫 | 切除可能な未分化多形肉腫 | 軟部組織線維肉腫 | 紡錘細胞肉腫 | ステージ I 後腹膜肉腫 AJCC (American Joint Committee on Cancer) v8 | 体幹および四肢の I 期軟部肉腫 AJCC v8 | ステージ... およびその他の条件アメリカ
biopsy to obtain a chemogramの臨床試験
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityFifth Affiliated Hospital, Sun Yat-Sen University募集
-
University of Alabama at BirminghamNational Cancer Institute (NCI)募集